Glaser Dee Anna, Hebert Adelaide A, Pariser David M, Solish Nowell
Department of Dermatology, Saint Louis University, Missouri, USA.
Cutis. 2007 May;79(5 Suppl):29-32.
Facial hyperhidrosis (HH) is more difficult to diagnose than other forms of focal HH because many secondary causes must be considered. Pharmacologic treatment with botulinum toxin type A (BTX-A) would be appropriate for patients with severe facial HH that limits their lifestyle (eg, blurred vision from sweating, distressed with their appearance). The main concern with administering BTX-A for facial HH is aesthetics, such as facial asymmetry or brow ptosis. This article describes best practice techniques for BTX-A (Botox) in patients with facial HH, including suggested dilution and syringe selection, injection technique, dose and injection grid, and anesthesia recommendations. Special considerations and navigating the insurance reimbursement process also are discussed.